Evidence map›Paper›PMID 34269799›Full record

ArticleBlood advances2021

CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.

Matteo Grioni, Arianna Brevi, Elena Cattaneo, Alessandra Rovida, Jessica Bordini, Maria Teresa Sabrina Bertilaccio, Maurilio Ponzoni, Giulia Casorati, Paolo Dellabona, Paolo Ghia and 2 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. NF-kB and the CLL microenvironment.Frontiers in oncology · 2023
    Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Matteo GrioniCellular Immunology Unit, Division of Immunology, Transplantation, and Infectious Diseases.
Arianna BreviCellular Immunology Unit, Division of Immunology, Transplantation, and Infectious Diseases.
Elena CattaneoCellular Immunology Unit, Division of Immunology, Transplantation, and Infectious Diseases.
Alessandra RovidaUnit of B Cell Neoplasia, Division of Experimental Oncology, and.
Jessica BordiniUnit of B Cell Neoplasia, Division of Experimental Oncology, and.
Maria Teresa Sabrina BertilaccioUnit of Lymphoid Malignancies, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0002-2586-2569
Maurilio PonzoniUnit of Lymphoid Malignancies, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Giulia CasoratiExperimental Immunology Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.
Paolo DellabonaExperimental Immunology Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0002-5102-4112
Paolo GhiaUnit of B Cell Neoplasia, Division of Experimental Oncology, and.
Matteo BelloneCellular Immunology Unit, Division of Immunology, Transplantation, and Infectious Diseases.ORCID 0000-0002-2586-2569
Arianna CalcinottoCellular Immunology Unit, Division of Immunology, Transplantation, and Infectious Diseases.ORCID 0000-0003-1746-6424
IRCCS Ospedale San Raffaele · ITVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is caused by the progressive accumulation of mature CD5+ B cells in secondary lymphoid organs. In vitro data suggest that CD4+ T lymphocytes also sustain survival and proliferation of CLL clones through CD40L/CD40 interactions. In vivo data in animal models are conflicting. To clarify this clinically relevant biological issue, we generated genetically modified Eμ-TCL1 mice lacking CD4+ T cells (TCL1+/+AB0), CD40 (TCL1+/+CD40-/-), or CD8+ T cells (TCL1+/+TAP-/-), and we monitored the appearance and progression of a disease that mimics aggressive human CLL by flow cytometry and immunohistochemical analyses. Findings were confirmed by adoptive transfer of leukemic cells into mice lacking CD4+ T cells or CD40L or mice treated with antibodies depleting CD4 T cells or blocking CD40L/CD40 interactions. CLL clones did not proliferate in mice lacking or depleted of CD4+ T cells, thus confirming that CD4+ T cells are essential for CLL development. By contrast, CD8+ T cells exerted an antitumor activity, as indicated by the accelerated disease progression in TCL1+/+TAP-/- mice. Antigen specificity of CD4+ T cells was marginal for CLL development, because CLL clones efficiently proliferated in transgenic mice whose CD4 T cells had a T-cell receptor with CLL-unrelated specificities. Leukemic clones also proliferated when transferred into wild-type mice treated with monoclonal antibodies blocking CD40 or into CD40L-/- mice, and TCL1+/+CD40-/- mice developed frank CLL. Our data demonstrate that CD8+ T cells restrain CLL progression, whereas CD4+ T cells support the growth of leukemic clones in TCL1 mice through CD40-independent and apparently noncognate mechanisms.

Indexed as

DromaiidaeLeukemia, Lymphocytic, Chronic, B-CellAnimalsCD40 LigandCD4-Positive T-LymphocytesMiceMice, TransgenicProto-Oncogene ProteinsCD40 LigandProto-Oncogene ProteinsTcl1 protein, mouse

Identifiers

PMID34269799
PMCPMC8341348
OpenAlexW3179489152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.